Effect of glucagon-like peptide 1 receptor agonists on album
Medline Ovid, Scopus, Web of Science, EMCARE, and CINAHL databases from database inception until January 27th, 2022. Studies were eligible for inclusion if they were randomised controlled trials (RCT) that involved treatment with a GLP-1RA in adult patients with T2DM and assessed the effect on albuminuria in each treatment arm. Data extraction was conducted independently by 3 individual reviewers. The PRISMA guidelines were followed regarding data extraction and quality assessment. Data was pooled using a random effects inverse variance model and all analysis was carried out with RevMan 5.4 software. The Jadad scoring tool was employed to assess the quality of evidence and risk of bias in the RCTs

The initial search revealed 2419 articles, of which 19 were included in this study. An additional 3 articles were identified from handsearching references of included reviews. Therefore, a total of 22 articles comprising 39,714 patients were included. Meta-analysis suggested that use of GLP1-RAs was associated with a reduction in albuminuria in patients with T2DM (WMD -16.14%, -95% CI -18.42 to -13.86%; p<0.0001) compared to controls.

This meta-analysis indicates that GLP-1RAs are associated with significant reduction in albuminuria in adult patients with T2DM when compared to placebo.

Source: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14776?af=R